A Single Site Retrospective Analysis of the Safety and Efficacy of the Amgen COMMUNITY Study
In 2019, a novel respiratory virus surfaced that lead to severe complications in patients and a global pandemic. One of the major issues was COVID-19 associated ARDS. The mortality rate of patients who develop ARDS from a COIVD-19 infection is 45% and at this time there are not many safe and efficacious treatments for the virus. This project exams the Amgen COMMUNITY study at a single site for efficacy and safety. The Amgen study looked at three potential treatments for COVID-19 that would hopefully lessen the occurrence and severity of ARDS; therefore, leading to a lower mortality rate. The efficacy and safety of the Amgen COMMUNITY study was evaluated retrospectively from patients data who participated in the study at the Sunbeam site.